Codice QR

Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations

Abstract Oncogenic KRAS mutations drive metabolic reprogramming in pancreatic ductal adenocarcinoma (PDAC). Src-homology 2 domain-containing phosphatase 2 (SHP2) is essential for full KRAS activity, and promising dual SHP2/mitogen-activated protein kinase (MAPK) inhibition is currently being tested...

Descrizione completa

Salvato in:
Autori principali: Philipp Hafner, Steffen J. Keller, Xun Chen, Asma Alrawashdeh, Huda Jumaa, Friederike I. Nollmann, Solène Besson, Judith Kemming, Oliver Gorka, Tonmoy Das, Bismark Appiah, Ariane Lehmann, Mujia Li, Petya Apostolova, Bertram Bengsch, Robert Zeiser, Stefan Tholen, Oliver Schilling, Olaf Groß, Andreas Vlachos, Uwe A. Wittel, Dominik von Elverfeldt, Wilfried Reichardt, Melanie Boerries, Geoffroy Andrieux, Guus J. Heynen, Stefan Fichtner-Feigl, Luciana Hannibal, Dietrich A. Ruess
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2026-01-01
Serie:Signal Transduction and Targeted Therapy
Accesso online:https://doi.org/10.1038/s41392-025-02563-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi